Researchers from Memorial Sloan Kettering Cancer Center and the University of California, Los Angeles, have discovered that comorbidities in midlife can increase the risk of developing cancer and cancer-related mortality. The study, published in JAMA Network Open, analyzed data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) screening trial to investigate the impact of midlife comorbidities on future cancer risk and mortality.
The cohort included 128,999 adults aged 55 to 74 years who reported histories of 12 comorbid conditions, categorized into cardiovascular, respiratory, gastrointestinal, liver-related, and metabolic conditions. After a 20-year follow-up, respiratory and cardiovascular histories were linked to a higher overall cancer incidence, while metabolic, gastrointestinal, and liver conditions did not significantly increase pan-cancer risk.
However, each comorbid condition was associated with an increased risk of at least one specific cancer type. For example, liver conditions were strongly linked to future liver cancer, while metabolic conditions were associated with a higher risk of nine cancer types and a lower risk of four types.
Additionally, respiratory, cardiovascular, and metabolic conditions were correlated with an increased risk of cancer-specific mortality. These findings suggest that midlife comorbidities play a role in cancer development and mortality risk, highlighting the importance of early screening and management of chronic conditions for improved cancer prevention and outcomes.
The study underscores the need for public health strategies that focus on integrating comorbidity screening into routine cancer risk assessments to support personalized cancer prevention programs. By understanding the associations between chronic conditions and cancer risk, healthcare providers can tailor prevention efforts to individual patients, potentially reducing the burden of cancer in midlife and beyond.
For more information, you can refer to the original articles published in JAMA Network Open by Jessica A. Lavery et al and Siran M. Koroukian et al. This research opens up new possibilities for personalized cancer prevention strategies by evaluating comorbidity and multimorbidity as key factors in cancer risk assessment and management.
